Dr. Andrea Abbott

Thoracic medical oncologist · Memorial Sloan Kettering · United States (US) · Oncology

Tier 1STK-0050GoodOwner MSL JWJames Whitfield

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: NSCLC
Scientific interests: Brain metastasesImmunotherapy sequencing
Engagement preference: In person
Advisory boards: 1
Publications: 8
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 1: 4 per year (assumption)

Last engaged: 10 Sept 2026 (5 days ago)
Next planned contact: 10 Dec 2026
Last 6 months vs target: 50%
1 of 2 expected engagements

Insights from this stakeholder (1)

INS-0047Brain-metastasis subgroup data
10 Sept 2026 · Evidence gap
CriticalPrioritised

Engagement history (2)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
10 Sept 2026	Scientific exchange	In person	James Whitfield	Vantrexa	Brain-metastasis subgroup dataChemotherapy-free first line	1	—	Reviewed	ENG-0007
14 Jan 2026	Congress meeting	In person	Rachel Adeyemi	Vantrexa	Sequencing after progression	0	—	Reviewed	ENG-0095

Timeline

10 Sept 2026
Scientific exchange
Brain-metastasis subgroup data, Chemotherapy-free first line
14 Jan 2026
Congress meeting
Sequencing after progression

Related stakeholders (6)

Memorial Sloan Kettering

Dr. Oscar Yamamoto
Oncology pharmacist
Tier 3
Dr. Zoë Eriksen
Thoracic medical oncologist
Tier 1
Dr. Farah Kimura
Thoracic medical oncologist
Tier 3
Dr. Zoë Garcia
Academic nephrologist
Tier 1
Dr. Benedikt Dubois
Headache specialist
Tier 3
Dr. Sven Fischer
Allergist
Tier 3